Michael Geschwind, MD, PhD
|School||UCSF School of Medicine|
|Address||675 Nelson Rising Lane|
San Francisco CA 94143
Dr. Geschwind received his M.D.and Ph.D. in neuroscience through the National Institutes of Health (NIH)-sponsored Medical Scientist Training Program (MSTP) at the Albert Einstein College of Medicine in New York. He completed his internship in internal medicine at the University of California, Los Angeles (UCLA) Medical Center, his neurology residency at the Johns Hopkins University School of Medicine in Baltimore and his fellowship in behavioral neurology at the UCSF Memory and Aging Center (MAC). He is now on faculty in the UCSF Department of Neurology where he is an Associate Professor of Neurology at the Memory and Aging Center (MAC).
Dr. Geschwind evaluates new patients in the MAC clinic and participates in the continued management and care for these patients in the continuity clinic. He is active in the training of medical students, residents and neurobehavior fellows at UCSF. Dr. Geschwind teaches national courses, and lectures both nationally and internationally, on dementia including rapidly progressive dementias, such as prion diseases. He recently edited the recent American Academy of Neurology (AAN) Continuum Dementia edition and is on the AAN’s committee for dementia criteria.
Dr. Geschwind’s primary research interest is the assessment and treatment of rapidly progressive dementias, including prion diseases such as Jakob-Creutzfeldt disease (CJD). Dr. Geschwind helped establish an inpatient hospital program for the assessment of rapidly progressive dementias at UCSF, the first of its kind in the country. He helped to run the first ever U.S. treatment study for CJD. He also has an active research interest in cognitive dysfunction in movement disorders, such as Huntington’s Disease, Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy (PSP), other parkinsonian dementias, and neurogenetic disorders.
Dr. Geschwind is currently the site primary investigator for two clinical Huntington’s disease studies sponsored by the Huntington’s Study Group (HSG) - PREDICT-HD and DIMOND-HD. PREDICT-HD is a 10-year plus NIH-funded study in which we are following “pre-symptomatic patients” who are at-risk for HD to try to identify neurologic, neurocognitive, serological and imaging markers of early HD. HORIZON-HD is a Phase III study assessing the efficacy of Dimebon on cognitive function in manifest HD. Dr. Geschwind was the site PI for TETRA-HD, which resulted in the first FDA-approved drug, tetrabenazine, for use in HD. He also was a site PI for TREND-HD (studying the efficacy of Ethyl-EPA), DIMOND-HD (dimebon phase 2) and the first ever study on the treatment of cognitive impairment in patients with Cerebral Autosomal Dominant Arteriopathy Subcortical Infarcts and Leukoencephalopathy (CADASIL).
Derived automatically from this person's publications.
People in Profiles who have published with this person.
People who share related concepts with this person.